A Comparative Study to Evaluate Different Analytical Methods Used to Quantify a Fusion Protein and Two Types of IgG Molecules Produced in CHO Cell Line
Screening of Commercial Production Media and Harvest Depth Filters for AAV Production
Space Filling Designs
BiBo Pharma: A Global CDMO Leading in Advanced Biopharmaceutical Manufacturing Technologies
The global biomanufacturing capacity gap and budget constraints have ignited the “The Fourth Revolutionary Wave of Biologics Manufacturing”, with production sites expanding towards million-liter scales. In this context, Contract Development and Manufacturing Organizations (CDMOs) have become key players in global biomanufacturing. Initially, from 1980 to 2000, manufacturing relied on self-built systems with hundred-liter bioreactors, resulting in […]
Perseverance Prevails: BiBo Pharma Celebrates One-Year Anniversary of Successful First-Run 30,000L Production Line
On March 28, 2024, as the final drop of product was successfully harvested, BiBo achieved an industry marvel—”Right on the First Time, Success on the First Time” in process scale-up production on its newly operational 30,000-liter production platform! This milestone not only marks the official industrialization of the world’s fourth-generation bioreactor but also solidifies BiBo’s […]
Bibo Celebrates the Spring Festival with a Promising Start! Successful Delivery of the First 30,000 Liters in 2025
In early March, Bibo successfully completed its first 30,000-liter mammalian cell (CHO) production task in 2025 This production task coincided with Chinese New Year holiday. Guided by customer needs, the Bibo team remained dedicated on the production front, employing scientific scheduling and meticulous management to ensure an uninterrupted production process. Through the collaborative efforts of […]
Pathway to $10/g Biologics Production: Reshaping the Biomanufacturing Landscape
The high cost of biologics is one of the biggest barriers to global healthcare access. Today, biologic therapies are largely confined to developed countries with a GDP per capita of $12,000 or more—leaving billions without access. But what if we could change that? Join us on February 18, 2025, as Dr. Peng Jiao, Founder & […]
The Grand-CHO Platform
The Grand-CHO Platform is the Boston Institute of Biotechnology’s groundbreaking innovation, revolutionizing biopharmaceutical production by integrating advanced cell line development, process optimization, and cutting-edge manufacturing technologies. This “Three-in-One” approach has positioned the Boston Institute of Biotechnology as a leader in cost-efficient, scalable biologics manufacturing. Enhanced Cell Line Development Central to the Grand-CHO Platform is the second-generation […]
BIB Wins Global Biologics CDMO Technology Leadership Award
Boston, MA – September 6, 2024 – The Boston Institute of Biotechnology, LLC (BIB) is proud to announce that its CEO has been awarded the prestigious 2024 Global Biologics CDMO Technology Leadership Award from Frost & Sullivan. This recognition celebrates BIB’s groundbreaking contributions to biologics manufacturing. This includes the world’s first 30,000L bioreactor and its […]
The Role of Quality Control in Biomanufacturing
Understanding the Crucial Role of Quality Control in Biomanufacturing In the dynamic field of biotechnology, ensuring the safety and efficacy of products is paramount. At the heart of this assurance lies quality control (QC), a critical function in biomanufacturing that upholds the highest standards and regulatory compliance. In this article, we delve into the importance […]